Interventions for cough in cancer

Molassiotis, Alex; Bailey, Chris; Caress, Ann Louise; Brunton, Lisa; Smith, Jaclyn A.

doi:10.1002/14651858.cd007881.pub2

Cited by 23 publications

(18 citation statements)

References 69 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In conclusion, using validated objective and subjective cough assessment tools we confirm that cough is a severe and distressing symptom in patients with lung cancer. Current antitussive therapies have limited efficacy with a weak evidence base 25 . Importantly, gastrointestinal symptoms demonstrated an association with cough rather than smoking, cancer stage, location, treatment and COPD.…”

Section: Discussionmentioning

confidence: 99%

Cough in Patients With Lung Cancer

Harle

Blackhall

Molassiotis

et al. 2019

Chest

Self Cite

View full text Add to dashboard Cite

Background: Cough is common in patients with lung cancer and current antitussive treatments are suboptimal. There is little published data describing cough in patients with lung cancer or work assessing clinical associations; the aim of the current is study is to fill that gap. Methods: Longitudinal prospective observational single-cohort study over 60 days. Patients were assessed through self-reported validated scales and, in a subsample, ambulatory cough monitoring, at study entry (day 0), day 30 and day 60. Results: At study entry, 177 patients were included and 153 provided data at day 60. The median duration of cough was 52 weeks (IQR 8.5-260). Cough was described as severe enough to warrant treatment in 62% of the patients. Depending on the scale used, performance status was associated with both cough severity and cough impact (p<0.001) at study entry, while higher cough severity at study entry was associated with female sex (p=0.02), asthma (p=0.035), and reflux disease (p<0.001); cough impact at study entry was additionally associated with experiencing nausea (p=0.018). Cancer characteristics (i.e. cancer stage, histology) were not associated with cough severity nor cough impact; neither was smoking or COPD. Conclusions: This is the first study to describe characteristics of cough in patients with lung cancer and identify clinical associations that may be relevant for its treatment. Our data suggest that cough is a frequent and distressing symptom, and an unmet clinical need. Its associationwith gastro-intestinal symptoms in this study may improve our understanding of pathophysiology and therapeutic options for cough occurring in patients with lung cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Cough in Patients With Lung Cancer

Harle

Blackhall

Molassiotis

et al. 2019

Chest

Self Cite

View full text Add to dashboard Cite

show abstract

“…A literature review preceded the meetings over the previous year, with two systematic reviews being undertaken, one with a focus on cough and respiratory illnesses (other than cancer) [11] and a second Cochrane review with a focus specifically in cancer [12]. Other publications, including reviews, case study reports and phase II trials that were not part of the systematic reviews were also retrieved and summarized.…”

Section: Process Of Guidelines Developmentmentioning

confidence: 99%

“…Research into cancer-related cough was even more disappointing, and our Cochrane systematic review [12] identified only 17 studies meeting the inclusion criteria. Almost half were studies investigating the effects of brachytherapy and nine trials assessed the effectiveness of a number of drugs (Table 1).…”

Section: Review Of the Evidencementioning

confidence: 99%

Clinical expert guidelines for the management of cough in lung cancer: report of a UK task group on cough

Molassiotis

Smith

Bennett

et al. 2010

Cough

Self Cite

View full text Add to dashboard Cite

BackgroundCough is a common and distressing symptom in lung cancer patients. The clinical management of cough in lung cancer patients is suboptimal with limited high quality research evidence available. The aim of the present paper is to present a clinical guideline developed in the UK through scrutiny of the literature and expert opinion, in order to aid decision making in clinicians and highlight good practice.MethodsTwo systematic reviews, one focusing on the management of cough in respiratory illness and one Cochrane review specifically on cancer, were conducted. Also, data from reviews, phase II trials and case studies were synthesized. A panel of experts in the field was also convened in an expert consensus meeting to make sense of the data and make clinical propositions.ResultsA pyramid of cough management was developed, starting with the treatment of reversible causes of cough/specific pathology. Initial cough management should focus on peripherally acting and intermittent treatment; more resistant symptoms require the addition of (or replacement by) centrally acting and continuous treatment. The pyramid for the symptomatic management starts from the simpler and most practical regimens (demulcents, simple linctus) to weak opioids to morphine and methadone before considering less well-researched and experimental approaches.ConclusionThe clinical guidelines presented aim to provide a sensible clinical approach to the management of cough in lung cancer. High quality research in this field is urgently required to provide more evidence-based recommendations.

show abstract

“…Długotrwały, męczący kaszel wpływa negatywnie na jakość życia [6] i stanowi dodatkowy czynnik potęgujący zmęczenie towarzyszące chorobie nowotworowej oraz prowadzący do stanu wyczerpania fizycznego. Jest również objawem skutkującym pogorszeniem kontroli innych objawów (m.in.…”

Section: Epidemiologiaunclassified

Cough – the diagnosis and treatment in palliative care patients

Zasowska-Nowak¹,

Ciałkowska-Rysz²

2018

View full text Add to dashboard Cite

Częstość występowania kaszlu przewlekłego u osób objętych opieką paliatywną wynosi 10-70% wśród chorych na nowotwory oraz 60-95% wśród chorych na zaawansowane choroby układu oddechowego i układu krążenia. U chorych na nowotwory kaszel może być objawem choroby podstawowej, powikłaniem stosowanego leczenia lub objawem schorzeń współistniejących. Długotrwały, uciążliwy kaszel jest objawem wpływającym negatywnie na jakość życia pacjentów, stanowiącym dodatkowy czynnik potęgujący zmęczenie towarzyszące chorobie nowotworowej, prowadzącym do stanu wyczerpania fizycznego, zaburzeń snu, złej kontroli innych objawów (m.in. bólu i duszności) oraz pogorszenia relacji towarzyskich. Określenie przyczyn kaszlu pozwala na wdrożenie odpowiedniego postępowania, w którym istotne znaczenie ma leczenie przyczynowe (o ile jest możliwe), odstawienie leków nasilających odruch kaszlowy, optymalizacja leczenia chorób współistniejących oraz włączenie postępowania niefarmakologicznego. Zastosowanie leków przeciwkaszlowych o potwierdzonej skuteczności (lewodropropizyna, butamirat, morfina, kodeina, dihydrokodeina, dekstrometorfan, kromoglikan sodowy) należy rozważyć w przypadku braku skuteczności powyższego postępowania.

show abstract

Interventions for cough in cancer

Cited by 23 publications

References 69 publications

Cough in Patients With Lung Cancer

Cough in Patients With Lung Cancer

Clinical expert guidelines for the management of cough in lung cancer: report of a UK task group on cough

Cough – the diagnosis and treatment in palliative care patients

Contact Info

Product

Resources

About